Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
8-pMeOPT-2'-O-Me-cAMP (also known as 8-pMeOPT) is a cell-permeable, stable, and highly selective agonist of the Exchange Protein directly Activated by cAMP (Epac). It is a synthetic analog of cyclic AMP (cAMP) designed with a 2'-O-methyl modification that renders it nearly inactive toward Protein Kinase A (PKA), and an 8-para-methoxyphenylthio (pMeOPT) substitution that increases its affinity for Epac1 and Epac2. As a specialized research tool, it allows for the isolated study of Epac-mediated signaling pathways, such as those involving Rap1 activation, calcium mobilization, and cytoskeletal dynamics. In the context of oncology research, specifically melanoma, 8-pMeOPT has been used to demonstrate that Epac activation promotes cell migration through the PLCε/IP3 receptor 1 pathway and subsequent Ca2+-dependent actin assembly.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on 8-pMeOPT-2'-O-Me-cAMP.